Gastaldelli A, Abdul Ghani M, DeFronzo RA
This recognition highlights our commitment to reducing our carbon footprint and environmental stewardship, labor practices, ethics and supply chain management
Metabolic and riskstratification considerations Age, metabolicstatus, and comorbidities influence the risk of malignancy, ischemicevents, or medicationrelated bleeding, necessitating tailored counseling and riskassessment for anemia, hemodynamicinstability, or recurrent hemorrhage
Therefore, the combined use of GLP-1 RAs with therapies targeting intrahepatic pathways, such as thyroid hormone receptor (THR-) agonists, fibroblast growth factor-21 (FGF21) analogues, and peroxisome proliferator-activated receptor (PPAR) agonists, presents a promising approach for MASH treatment